Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paliperidone palmitate
Drug ID BADD_D01657
Description Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Indications and Usage As an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection, paliperidone is indicated for the treatment of adults and adolescents with schizophrenia and in the treatment of schizoaffective disorder in combination with antidepressants or mood stabilizers.[L16168,L37744] Paliperidone is also available in both an every-three-month and twice-yearly extended-release suspension for intramuscular injection for the treatment of schizophrenia.[L4137,L37749]
Marketing Status approved
ATC Code N05AX13
DrugBank ID DB01267
KEGG ID D05340
MeSH ID D000068882
PubChem ID 9852746
TTD Drug ID D0B3UJ
NDC Product Code 58032-1010; 64552-4063; 50458-609; 14501-0069; 50458-560; 64552-4076; 65372-1174; 68108-0630; 65089-0047; 50458-562; 50458-606; 55111-926; 47848-058; 50458-607; 50458-611; 64552-4037; 64552-4066; 50458-561; 50458-563; 65085-0066; 50458-564; 50458-608; 50458-612
UNII R8P8USM8FR
Synonyms Paliperidone Palmitate | Palmitate, Paliperidone | Paliperidone | 9-OH-risperidone | 9 OH risperidone | 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one | 9-Hydroxy-risperidone | 9 Hydroxy risperidone | 9-Hydroxyrisperidone | 9 Hydroxyrisperidone | Invega | Invega Sustenna | Sustenna, Invega | R 76477 | R-76477 | R76477
Chemical Information
Molecular Formula C39H57FN4O4
CAS Registry Number 199739-10-1
SMILES CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.05.027--Not Available
Parkinsonian gait17.01.05.005; 08.01.02.005--Not Available
Cognitive disorder17.03.03.003; 19.21.02.001--
Haematology test abnormal13.01.03.002--Not Available
Metabolic disorder14.11.01.001--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Hyperinsulinaemia14.06.03.005; 05.06.03.005--Not Available
Induration08.01.03.020--Not Available
Blood test abnormal13.18.01.003--Not Available
Eye movement disorder17.02.05.025; 06.05.02.008--Not Available
Ischaemia24.04.02.004--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Temperature regulation disorder05.03.04.013; 08.05.01.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Urine analysis abnormal13.13.02.008--Not Available
Postural orthostatic tachycardia syndrome17.05.01.019; 02.03.02.020--Not Available
Oromandibular dystonia17.01.03.006--Not Available
The 5th Page    First    Pre   5    Total 5 Pages